Search Results - discovery

10 Results

Sort By:

Aberrant Post-translational Modifications (PTMs) in Methyl- and Propionic Acidemia and the Construction of a Novel Sirtuin (SIRT) Gene to Metabolize PTMs

Isolated Methylmalonic Acidemia (MMA) and the related disorder Propionic Acidemia (PA) comprise a relatively common and heterogeneous group of inborn errors of metabolism. NHGRI scientist discovered that in isolated MMA, a novel inhibitory PTM, methylmalonyllysine, is generated and inactivates protein targets through the failure of SIRT-mediated deacylation,...

Published: 7/25/2024 | Inventor(s): PamelaSara Head, Charles Venditti

Keywords(s): Aberrant, Acidemia, Construction, Discovery, Ene, Metabolize, Methyl-, Modifications, Novel, Post-translational, Propionic, PTMs, Sirt, Sirtuin, VPXXXX, WIXXXX, WKXXXX, XEXXXX

Category(s): TherapeuticArea > Endocrinology, TherapeuticArea > Dental, TherapeuticArea > Oncology, TherapeuticArea > Cardiology, TherapeuticArea > Ophthalmology, Application > Therapeutics, TherapeuticArea > Infectious Disease, Application > Research Materials

Creation and Use of 12-LO inhibitors (4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide derivatives) for the Treatment of Diabetes and Large Platelet-Derived Clots

This technology includes the discovery and use of novel selective 12-LO (lipoxygenase) inhibitors, 4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide derivatives, for attenuating large clots and for the treatment of Type 1/2 diabetes. A 12-LO inhibitor could be a potent intracellular approach to block platelets from forming large clots in response...

Published: 7/25/2024 | Inventor(s): Ajit Jadhav, Anton Simeonov, Adam Yasgar, Diane Luci, Michael Holinstat, Theodore Holman, Jerry Nadler, David Taylor-Fishwick, David Maloney

Keywords(s): 12-Lipoxygenase., 4-2-hydroxy-3-methoxybenzylaminobenzenesulfon, Derivatives, Discovery, Human, Inhibitors, Listed LPM Nguyen-Antczak as of 4/15/2015, Post LPM Assignment Set 20150420, POTENT, Pre LPM working set 20150418, SELECTIVE, VDXXXX, VFXXXX, WKXXXX, XEXXXX

Category(s): TherapeuticArea > Cardiology, TherapeuticArea > Endocrinology, Application > Therapeutics

Discovery of Proteasome Inhibitors to Target PMP22 Gene Expression for the Treatment of Charcot-Marie-Tooth Disease Type 1A

This technology includes the use of proteasome inhibitors, such as Bortezomib, for the treatment of the most prevalent form of Charcot-Marie-Tooth disease type 1A (CMT1A). Duplication of the peripheral myelin protein 22 (PMP22) gene, normally involved in myelination of the peripheral nervous system, is the causative agent in most forms of CMT1A. A drug...

Published: 7/25/2024 | Inventor(s): Sung-Wook Jang, John Svaren, James Inglese

Keywords(s): Discovery, DOWN, Expression, Gene, inhibition, Listed LPM Tong as of 4/15/2015, MEANS, Pmp22, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Proteasome, REGULATE, VEXXXX, WKXXXX, XEXXXX

Category(s): Application > Therapeutics, TherapeuticArea > Neurology

Discovery of imidazo[1,2-b]pyridazines with Anticancer Properties

This technology includes a series of imidazo[1,2-b]pyridazines that display potent inhibition of FLT3, as well as potent binding and activity against FLT3 tyrosine kinase domain and gatekeeper mutations. This chemotype exhibits superior anti-leukemic activity against the common clinically-relevant FLT3-mutant acute myeloid leukemia (AML) in vitro and...

Published: 7/25/2024 | Inventor(s): Scott Hoyt, Patrick Sutter, Chris Finocchio, Daniel Starczynowski, Gregory Tawa, Craig Thomas

Keywords(s): 2-b]pyridazines, ANTICANCER, Discovery, Imidazo[1, PROPERTIES, VCXXXX, WIXXXX, WKXXXX

Category(s): Application > Therapeutics, Application > Research Materials, TherapeuticArea > Oncology

Derivatives of Docosahexaenoylethanolamide (DEA) for Neurogenesis

The invention pertains to derivatives of docosahexaenoylethanolamide (synaptamide or DEA) and their use in inducing neurogenesis, neurite growth, and/or synaptogenesis. As such, these DEA derivatives can be used as therapeutics for neurodegenerative diseases such as traumatic brain injury, spinal cord injury, peripheral nerve injury, stroke, multiple...

Published: 7/25/2024 | Inventor(s): Erika Englund, Juan Marugan, Samarjit Patnaik, Hee-Yong Kim

Keywords(s): Derivatives, Development, Discovery, Docosahexaenoylamide, Growth, IB6XXX, IBXXXX, IXXXXX, Listed LPM Vepa as of 4/15/2015, NB1FXX, NB1HXX, NB1XXX, NBXXXX, Neurons, NXXXXX, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Promote, That, VEXXXX, YAXXXX, YBXXXX, YFXXXX

Category(s): Collaboration Sought > Licensing, TherapeuticArea > Neurology, Application > Diagnostics, TherapeuticArea > Reproductive Health, Application > Research Materials, Application > Vaccines, Application > Therapeutics

M3 Muscarinic Receptor Knockout Mice (Chrm3 tm1Jwe) for the Study of Obesity and Other Metabolic Disorders

The five Muscarinic Acetylcholine (ACh) receptors are G-protein coupled receptors (M1R-M5R). M3 muscarinic ACh receptors are present in the central nervous system and the periphery. M3R knockout mice are viable and fertile, and have no major morphological abnormalities. They have a lean phenotype due to a combination of reduced caloric intake and...

Published: 7/25/2024 | Inventor(s): Jurgen Wess

Keywords(s): ACXXXX, AXXXXX, Discovery, DOUBLE, DRUG, Generation, ID1XXX, IDXXXX, IXXXXX, KnockoutKO, M1/M3, M1/M4, M2/M3, M2/M4, Mice:, MUSCARINIC, Novel, RECEPTOR, TOOLS

Category(s): Collaboration Sought > Licensing, Application > Research Materials, Application > Diagnostics, Application > Therapeutics

Selective 12-Human Lipoxygenase Inhibitors for the Treatment of Diabetes and Clotting

This invention discloses small molecule inhibitors of human 12-lipoxygenase (12-hLO). 12-lipoxygenase expression, activation, and lipid metabolites have been implicated in type 1 and type 2 diabetes, cardiovascular disease, hypertension, Alzheimer’s, and Parkinson’s disease. The development of 12-hLO inhibitors may be a potent intracellular approach...

Published: 7/25/2024 | Inventor(s): Jerry Nadler, Michael Holinstat, Anton Simeonov, Ajit Jadhav, Theodore Holman, David Maloney

Keywords(s): 12-human, Cardiovascular, CAUSED, Clot, DIABETES, Discovery, Disease, Formation, IA1AXX, IA1XXX, IAXXXX, Inhibitors, IXXXXX, LIPOXYGENASE, Platelet-mediated, Prevention, SELECTIVE, treatment

Category(s): Collaboration Sought > Licensing, Application > Research Materials, TherapeuticArea > Cardiology, Application > Therapeutics, Application > Diagnostics

Compounds That Treat Malaria and Prevent Malaria Transmission

Malaria is the single leading cause of death, especially among children, in the developing world. Malaria is caused by infection with parasites of the genus Plasmodium, transmitted by mosquitos. In addition to transmission, vital steps in the parasite lifecycle occur in the mosquito host. The invention offered for licensing relates to therapeutic compounds...

Published: 7/25/2024 | Inventor(s): Jing Yuan, Sittiporn Pattaradilokrat, Ruili Huang, Ronald Johnson, Dipak Raj, Xin-zhuan Su

Keywords(s): ANTIMALARIAL, DB2XXX, DBXXXX, Discovery, DRUGS, DXXXXX, Malaria (Plasmodium sp.), Potential, UBXXXX, UXXXXX

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Infectious Disease, TherapeuticArea > Rare / Neglected Diseases

Agonist Epitopes for Renal Cell Carcinoma

Approximately 30,000 patients are diagnosed with renal cell carcinoma (RCC) each year in the United States, and an estimated 12,000 patients die of this disease. Most patients are diagnosed with advanced local disease or metastatic disease. Metastatic RCC carries a poor prognosis with median survivals in the range of 10-12 months. Drugs that inhibit...

Published: 7/25/2024 | Inventor(s): Richard Childs

Keywords(s): BBXXXX, CA1AXX, CA1XXX, CA2CXX, CA2XXX, Carcinoma, CAXXXX, CB2BXX, CB2XXX, CB4XXX, CBXXXX, Cell, Cells, CXXXXX, Discovery, Expression, Gene, Kidney cancer, adult, Patent Category - Biotechnology, previously, RDD, RENAL, Renal cell carcinoma 1, Renal cell carcinoma 4, Restricted, Uncharacterized, WHOSE

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Diagnostics, Application > Vaccines, Application > Therapeutics, TherapeuticArea > Oncology

Novel Methods for Reducing Inflammation and Treating Diseases such as Parkinson's and Alzheimer's Disease

Microglia activation leads to inflammation mediated dopaminergic degeneration in the brain of patients with Parkinson and Alzheimer's Disease. Thus Identification of drugs that reduce microglia activation could prevent or reverse neuronal degeneration in these diseases and other degenerative CNS disorders. This invention describes small-peptide and...

Published: 7/25/2024 | Inventor(s): Liya Qin, Guorong Li, MIchelle Block, Wei Zhang, Po-See Chen, Giia-Shuen Peng, Jau-Shyong Hong

Keywords(s): Alzheimer disease 1, Alzheimer disease 3, Alzheimer disease 4, Alzheimer disease type 1, Alzheimer disease type 4, Alzheimer disease, familial, type 3, BBXXXX, Discovery, DOSE, femto-molar, IB3XXX, IBXXXX, Inflammation-associated, IXXXXX, Listed LPM Greene as of 4/15/2015, NB1BXX, NBXXXX, NEURODEGENERATIVE, NXXXXX, Parkinson disease 2, Parkinson disease 3, Parkinson disease 9, Parkinson disease, juvenile, autosomal recessive, Parkinson's, Patent Category - Biotechnology, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Prevention, therapeutic, therapeutics, Ultra-low, VEXXXX, WJXXXX, WKXXXX, YAXXXX, YBXXXX, YCXXXX

Category(s): Collaboration Sought > Collaboration, Application > Therapeutics, TherapeuticArea > Neurology, TherapeuticArea > Immunology, Application > Diagnostics, Application > Research Materials